Galapagos creates new warrant plan MECHELEN, Belgium, Oct.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos creates new warrant plan

MECHELEN, Belgium, Oct. 17, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced that its Board of Directors has created and offered 150,000 warrants under a new warrant plan.

The Board of Directors of Galapagos approved the "Warrant Plan 2014 (B)" within the framework of the authorized capital on 14 October 2014. Under this warrant plan, 150,000 warrants were created (subject to acceptance) and offered to Bart Filius, who will join Galapagos as Chief Financial Officer, effective 1 December 2014.

These warrants have an exercise term of eight years as of the date of the offer and have an exercise price of €11.93 (the average closing price of the share on Euronext Brussels during the thirty days preceding the date of the offer).  The warrants are not transferable and can in principle not be exercised prior to the end of the third calendar year after the calendar year in which they were granted. Each warrant gives the right to subscribe to one new Galapagos share. Should the warrants be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market. The warrants as such will not be listed on any stock market.

To date, Galapagos' total share capital amounts to €163,868,834.64; the total number of securities conferring voting rights is 30,292,604, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,471,378, which equals the total number of voting rights that may result from the exercise of these warrants(but excludes the 150,000 warrants of Warrant Plan 2014 (B), which were created subject to acceptance).

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic disease. In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634 .  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease.  Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is expected to start Phase 1 in 2014. Galapagos also expects to nominate a pre-clinical candidate corrector before year end 2014.  The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  Further information at: www.glpg.com

Contact
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

HUG#1863952

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

ParagonX Holdings: Update on Company Transformation Plans

Updated Category News Views 146

ParagonX Holdings Shareholder Update ParagonX Holdings, Inc. (OTC:CAVR) recently shared insightful information regarding its transformation and strategic direction. The company is under the management of Caprino Management, LLC, which is actively assessing acquisition opportunities to bolster its growth. Divestitures and Debt Restructuring A significant step taken by...

Continue Reading
Applaud Receives Prestigious AI Award for Transforming HR

Updated Category News Views 300

Applaud Triumphs with Prestigious AI Award Applaud, a leading innovator in HR technology, has achieved significant recognition in the tech industry. The company’s generative-AI HR platform was awarded the flagship AI Award at a major international event. Applaud was selected among several finalists, showcasing its commitment to providing measurable value to employees...

Continue Reading
Empowering Stories: A Mother's Journey to a New Start

Updated Category News Views 257

Empowering Stories: A Mother's Journey to a New Start Anita's story is one of resilience. Faced with overwhelming challenges in her early life, she fought tirelessly to change her circumstances. Growing up without a family, she was married at a tender age to an older man, and for years, she juggled the responsibilities of motherhood while tending to her husband’s...

Continue Reading
First Capital REIT Declares Monthly Distribution for Investors

Updated Category News Views 176

First Capital REIT Announces Distribution for October 2025 First Capital REIT announces its cash distribution for October 2025, setting a notable precedent for its unitholders. The company has declared a distribution of $0.074167 per REIT unit, which translates to an annualized payout of $0.89 per unit. The payment is scheduled for November 17, 2025, to unitholders...

Continue Reading
Sidus Space and Other Major Stocks Experience Declines

Updated Category News Views 166

Stock Market Dynamics: Sidus Space and Others The U.S. stock market is seeing some fluctuations as futures showed little movement earlier today. Among these movements, Nasdaq 100 futures gently slipped by about 0.01%. In the midst of this, shares of Sidus Space, Inc. (NASDAQ: SIDU) are particularly noteworthy. Sidus Space's Price Adjustment Sidus Space recently made...

Continue Reading